To print this article, all you need is to be registered or login on Mondaq.com.
On 5 May 2021, the Department of Intellectual Property (DIP) of
Thailand rejected a Thai patent application for a granulated powder
tablet containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, also
known as Favipiravir, which is a drug used to treat viral
infections including COVID-19. Favipiravir has been used in many
countries including Thailand to treat COVID-19 patients.
With the spiking numbers of COVID-19 infections, demand for
Favipiravir has soared with fears of shortage. As Favipiravir can
currently only be imported into the country, Thailand aims to
establish a production hub for the Favipiravir tablets to meet